|
Variable
|
No.
|
3- year RC
|
pvalue
|
|---|
|
Age (years)
| | |
0.146
|
|
≤ 60
|
32
|
84.4
| |
|
> 60
|
18
|
61.9
| |
|
Gender
| | |
0.093
|
|
Male
|
41
|
72.0
| |
|
Female
|
9
|
100.0
| |
|
Primary site
| | |
0.22
|
|
Nasopharynx
|
25
|
83.6
| |
|
Non-Nasopharynx
|
25
|
72.0
| |
|
T classification
| | |
0.121
|
|
1
|
14
|
68.8
| |
|
2
|
19
|
84.2
| |
|
3
|
8
|
100
| |
|
4
|
9
|
55.6
| |
|
T classification
| | |
0.05
|
|
1-3
|
41
|
82.0
| |
|
4
|
9
|
55.6
| |
|
N classification
| | |
0.43
|
|
1
|
12
|
91.7
| |
|
2
|
30
|
71.9
| |
|
3
|
8
|
75.0
| |
|
N classification
| | |
0.194
|
|
1
|
12
|
91.7
| |
|
2-3
|
38
|
72.7
| |
|
Initial maximal lymph node size (cm)
| | |
0.022
|
|
≤ 2
|
28
|
88.0
| |
|
> 2
|
22
|
63.6
| |
|
RT modality
| | |
0.887
|
|
Conventional
|
4
|
75
| |
|
3D-CRT
|
25
|
73.8
| |
|
IMRT
|
21
|
81.0
| |
|
Chemotherapy sequence
| | |
0.123
|
|
Neoadjuvant + concurrent1
|
21
|
71.4
| |
|
Concurrent + adjuvant2
|
17
|
94.1
| |
|
Concurrent only
|
12
|
64.3
| |
|
Primary tumor response
| | |
< 0.001
|
|
Complete response
|
38
|
88.1
| |
|
Partial response
|
10
|
50.0
| |
|
Progressive disease
|
2
|
0.0
| |
|
Primary tumor response
| | |
< 0.001
|
|
Complete response
|
38
|
88.1
| |
|
Non-complete response
|
12
|
41.7
| |
|
Residual maximal lymph node size (cm)
| | |
< 0.001
|
|
≤ 1.5
|
45
|
83.5
| |
|
> 1.5
|
5
|
20.0
| |
|
Lymph node necrosis
| | |
< 0.001
|
|
No
|
41
|
87.8
| |
|
Yes
|
9
|
33.3
| |
|
Follow-up PET report
| | |
0.349
|
|
Residual disease
|
4
|
50
| |
|
Normal/Reactive change
|
27
|
78.1
| |
|
Not available
|
19
|
78.9
| |
- RC: regional control
- 1. Two patients who received neoadjuvant chemotherapy only were included
- 2. Four patients who received additional one cycle of neoadjuvant chemotherapy were included
